董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul A. Molloy | 男 | Director | 55 | 3.00万美元 | 未持股 | 2017-04-26 |
| Alan W. Milinazzo | 男 | Director | 57 | 3.00万美元 | 未持股 | 2017-04-26 |
| Kenneth R. Weisshaar | 男 | Director | 66 | 未披露 | 未持股 | 2017-04-26 |
| Kenneth R. Weisshaar | 男 | Director | 66 | 3.50万美元 | 未持股 | 2017-04-26 |
| Thomas M. Patton | 男 | Director,President and Chief Executive Officer | 53 | 50.23万美元 | 未持股 | 2017-04-26 |
| Gregory P. Rainey | 男 | Director | 64 | 3.00万美元 | 未持股 | 2017-04-26 |
| James E. Thomas | 男 | Director | 56 | 3.00万美元 | 未持股 | 2017-04-26 |
| Kathleen A. Tune | 女 | Director | 52 | 3.00万美元 | 未持股 | 2017-04-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffery A. Baird | 男 | Chief Financial Officer and Secretary | 63 | 31.13万美元 | 未持股 | 2017-04-26 |
| Thomas M. Patton | 男 | Director,President and Chief Executive Officer | 53 | 50.23万美元 | 未持股 | 2017-04-26 |
| Paul B. Benni | 男 | Chief Scientific Officer | 49 | 未披露 | 未持股 | 2017-04-26 |
| John K. Gamelin | 男 | Vice President - Research and Development | 51 | 27.89万美元 | 未持股 | 2017-04-26 |
董事简历
中英对照 | 中文 | 英文- Paul A. Molloy
-
Paul A. Molloy， 目前是一家专注于手术后伤口处理的早期医疗设备公司- ClearFlow Inc.的首席执行官。2010-2013年，在担任血管部总裁；以及在一家血管超声导航技术公司- VasoNova, Inc.担任首席执行官，该公司后被Teleflex收购。2008-2010年，在一家专注于心脏病的医疗设备公司- MiCardia Corporation担任总裁和首席执行官。有着在医疗设备行业超过20年的管理经验，目前在私营企业ClearFlow Inc.和Velano Vascular, Inc.的董事会任职。是荷兰（Netherlands）Utrecht市Instituut der Bedrijfswetenschappen的一名毕业生；持有Chicago大学Booth商学院的工商管理硕士学位。
Paul A. Molloy is currently the Chief Executive Officer of ClearFlow Inc., a commercial-stage medical device company focused on post-surgical wound management. From 2010 to 2013 Mr. Molloy served as the President of the Vascular Division of Teleflex Inc. NYSE: TFX and as the Chief Executive Officer of VasoNova, Inc., a vascular ultrasound navigation technology company, which was acquired by Teleflex. From 2008 to 2010 Mr. Molloy served as the President and Chief Executive Officer of MiCardia Corporation, a medical device company focused on cardiology. Mr. Molloy has over 25 years of management experience in the medical device industry and currently serves on the Board of Directors of privately-held ClearFlow Inc. and Velano Vascular, Inc. He is a graduate of the Instituut der Bedrijfswetenschappen, Utrecht, Netherlands, and has an M.B.A. from the University of Chicago Booth School of Business. - Paul A. Molloy， 目前是一家专注于手术后伤口处理的早期医疗设备公司- ClearFlow Inc.的首席执行官。2010-2013年，在担任血管部总裁；以及在一家血管超声导航技术公司- VasoNova, Inc.担任首席执行官，该公司后被Teleflex收购。2008-2010年，在一家专注于心脏病的医疗设备公司- MiCardia Corporation担任总裁和首席执行官。有着在医疗设备行业超过20年的管理经验，目前在私营企业ClearFlow Inc.和Velano Vascular, Inc.的董事会任职。是荷兰（Netherlands）Utrecht市Instituut der Bedrijfswetenschappen的一名毕业生；持有Chicago大学Booth商学院的工商管理硕士学位。
- Paul A. Molloy is currently the Chief Executive Officer of ClearFlow Inc., a commercial-stage medical device company focused on post-surgical wound management. From 2010 to 2013 Mr. Molloy served as the President of the Vascular Division of Teleflex Inc. NYSE: TFX and as the Chief Executive Officer of VasoNova, Inc., a vascular ultrasound navigation technology company, which was acquired by Teleflex. From 2008 to 2010 Mr. Molloy served as the President and Chief Executive Officer of MiCardia Corporation, a medical device company focused on cardiology. Mr. Molloy has over 25 years of management experience in the medical device industry and currently serves on the Board of Directors of privately-held ClearFlow Inc. and Velano Vascular, Inc. He is a graduate of the Instituut der Bedrijfswetenschappen, Utrecht, Netherlands, and has an M.B.A. from the University of Chicago Booth School of Business.
- Alan W. Milinazzo
-
Alan W. Milinazzo目前是Heidrick & Struggles咨询公司的合伙人。从2013年到2016年，他担任InspireMD, Inc.(一家上市的介入设备公司，专注于开发新型栓塞保护产品)的总裁兼首席执行官。从2005年到2012年，他担任Orthofix International, N.V.(上市的全球骨科公司)的首席执行官和董事。2002年至2005年，他担任Medtronic Inc.的血管业务副总裁、冠状动脉和外围业务副总裁兼总经理。Milinazzo先生还曾担任Boston Scientific Corporation的执行职务。除了担任肌肉骨骼移植基金会的董事会成员外，他还担任Flexion Therapeutics Inc.的董事会成员。他曾担任inspirremd, Inc.的董事会成员;Orthofix International, N.V.;Medpace;和HET系统。Milinazzo先生以优异成绩毕业于波士顿学院。
Alan W. Milinazzo is currently a Partner of the consulting firm of Heidrick & Struggles. From 2013 to 2016 he served as President and Chief Executive Officer of InspireMD, Inc., a publicly-traded interventional device company focused on developing novel embolic protection products. From 2005 to 2012 he served as Chief Executive Officer and Director of Orthofix International, N.V., a publicly-traded global orthopedic company. From 2002 to 2005 he served as Vice President of the vascular business as well as Vice President and G.M. of the coronary and peripheral businesses at Medtronic Inc. Mr. Milinazzo also served in executive positions at Boston Scientific Corporation. In addition to being a board member on the board of the Musculoskeletal Transplant Foundation, he serves on the board of Flexion Therapeutics Inc. He formerly served on the boards of InspireMD, Inc.; Orthofix International, N.V.; Medpace; and HET Systems. Mr. Milinazzo graduated cum laude from Boston College. - Alan W. Milinazzo目前是Heidrick & Struggles咨询公司的合伙人。从2013年到2016年，他担任InspireMD, Inc.(一家上市的介入设备公司，专注于开发新型栓塞保护产品)的总裁兼首席执行官。从2005年到2012年，他担任Orthofix International, N.V.(上市的全球骨科公司)的首席执行官和董事。2002年至2005年，他担任Medtronic Inc.的血管业务副总裁、冠状动脉和外围业务副总裁兼总经理。Milinazzo先生还曾担任Boston Scientific Corporation的执行职务。除了担任肌肉骨骼移植基金会的董事会成员外，他还担任Flexion Therapeutics Inc.的董事会成员。他曾担任inspirremd, Inc.的董事会成员;Orthofix International, N.V.;Medpace;和HET系统。Milinazzo先生以优异成绩毕业于波士顿学院。
- Alan W. Milinazzo is currently a Partner of the consulting firm of Heidrick & Struggles. From 2013 to 2016 he served as President and Chief Executive Officer of InspireMD, Inc., a publicly-traded interventional device company focused on developing novel embolic protection products. From 2005 to 2012 he served as Chief Executive Officer and Director of Orthofix International, N.V., a publicly-traded global orthopedic company. From 2002 to 2005 he served as Vice President of the vascular business as well as Vice President and G.M. of the coronary and peripheral businesses at Medtronic Inc. Mr. Milinazzo also served in executive positions at Boston Scientific Corporation. In addition to being a board member on the board of the Musculoskeletal Transplant Foundation, he serves on the board of Flexion Therapeutics Inc. He formerly served on the boards of InspireMD, Inc.; Orthofix International, N.V.; Medpace; and HET Systems. Mr. Milinazzo graduated cum laude from Boston College.
- Kenneth R. Weisshaar
-
Kenneth R. Weisshaar目前是Orthofix International, N.V.（一家纳斯达克上市的矫形设备公司）的董事会成员；Weisshaar先生还在CenterLight Health System（一家大型的非营利性位于纽约城市地区的家庭护理和护理管理组织）的董事会任职；Weisshaar先生曾是Digene 公司（一家专注女性健康和分子诊断测试的上市公司）的董事会成员。2000年到2002年期间，Weisshaaar先生曾担任 Sensatex, Inc.（一家刚起步的开发无线生命体征监控设备的公司）的首席运营官和战略顾问。在那之前，Weisshaar先生曾在 Becton Dickinson Company（一家医学技术公司）担任公司官员12年，并在不同时期负责医疗设备和诊断产品的国际业务，并担任战略计划部的首席财务官。Weisshaaar先生还曾受雇于McKinsey，并主要担任保荐和生产顾问。Weisshaar先生获得了麻省理工学院化学工程学士学位和哈佛商学院的工商管理硕士学位。
Kenneth R. Weisshaar previously served as a member of the Board of Directors of Orthofix International, N.V., a Nasdaq-listed orthopedic device company, Digene Corporation, a publicly-traded biotechnology company focused on women’s health and molecular diagnostic testing, and CenterLight Health System, a large non-profit nursing home and managed care organization located in the New York City area. Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickinson and Company, a medical technology company where, at different times, he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar was also employed by McKinsey and Company primarily as a healthcare and manufacturing consultant. Mr. Weisshaar received a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from the Harvard Business School. - Kenneth R. Weisshaar目前是Orthofix International, N.V.（一家纳斯达克上市的矫形设备公司）的董事会成员；Weisshaar先生还在CenterLight Health System（一家大型的非营利性位于纽约城市地区的家庭护理和护理管理组织）的董事会任职；Weisshaar先生曾是Digene 公司（一家专注女性健康和分子诊断测试的上市公司）的董事会成员。2000年到2002年期间，Weisshaaar先生曾担任 Sensatex, Inc.（一家刚起步的开发无线生命体征监控设备的公司）的首席运营官和战略顾问。在那之前，Weisshaar先生曾在 Becton Dickinson Company（一家医学技术公司）担任公司官员12年，并在不同时期负责医疗设备和诊断产品的国际业务，并担任战略计划部的首席财务官。Weisshaaar先生还曾受雇于McKinsey，并主要担任保荐和生产顾问。Weisshaar先生获得了麻省理工学院化学工程学士学位和哈佛商学院的工商管理硕士学位。
- Kenneth R. Weisshaar previously served as a member of the Board of Directors of Orthofix International, N.V., a Nasdaq-listed orthopedic device company, Digene Corporation, a publicly-traded biotechnology company focused on women’s health and molecular diagnostic testing, and CenterLight Health System, a large non-profit nursing home and managed care organization located in the New York City area. Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickinson and Company, a medical technology company where, at different times, he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar was also employed by McKinsey and Company primarily as a healthcare and manufacturing consultant. Mr. Weisshaar received a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and an MBA from the Harvard Business School.
- Kenneth R. Weisshaar
-
Kenneth R. Weisshaar先生在2004年成为ORTHOFIX国际的董事。2000年至2002年，Weisshaar先生曾担任Sensatex公司的首席运营官和战略顾问。在此之前，Weisshaar先生在Becton Dickson公司工作了12年，担任公司行政人员。该公司是一家医疗设备公司，他是多次负责医疗器械和诊断产品的全球业务，并担任财务总监和战略规划副主管。Weisshaar先生获得了麻省理工学院（Massachusetts Institute of Technology ）的理学学士学位，和哈佛商学院（Harvard Business School）的工商管理硕士学位。他也是CAS医疗系统公司（CAS Medical Systems, Inc.）的董事，并作为董事会的审计委员会主席，该公司是一家为无创病人监护提供医疗器械的公开上市的制造商。在Digene公司（Digene Corporation）于2007年被收购之前，他还担任其4年的董事，该公司是一家公开上市的生物技术公司。他曾该公司董事会审计委员会主席及薪酬委员会成员。 Weisshaar先生还担任CenterLight卫生系统公司（CenterLight Health System）董事，该公司是纽约州非以营利为目的的长期护理最大供应商之一。
Kenneth R. Weisshaar, became a director of Orthofix International in 2004. From 2000 to 2002 Mr. Weisshaar served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Prior to that, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a Bachelor of Science degree from Massachusetts Institute of Technology and an MBA from Harvard Business School. He also serves on the board, and as chair of the board's audit committee, of CAS Medical Systems, Inc., a publicly traded manufacturer of medical devices for non-invasive patient monitoring. Prior to its acquisition in 2007 he also served for four years on the board of Digene Corporation, a publicly traded biotechnology company, where he was chair of the audit committee and a member of the compensation committee. Mr. Weisshaar also serves on the board of CenterLight Health System, one of the largest non-for-profit long-term care providers in New York State. - Kenneth R. Weisshaar先生在2004年成为ORTHOFIX国际的董事。2000年至2002年，Weisshaar先生曾担任Sensatex公司的首席运营官和战略顾问。在此之前，Weisshaar先生在Becton Dickson公司工作了12年，担任公司行政人员。该公司是一家医疗设备公司，他是多次负责医疗器械和诊断产品的全球业务，并担任财务总监和战略规划副主管。Weisshaar先生获得了麻省理工学院（Massachusetts Institute of Technology ）的理学学士学位，和哈佛商学院（Harvard Business School）的工商管理硕士学位。他也是CAS医疗系统公司（CAS Medical Systems, Inc.）的董事，并作为董事会的审计委员会主席，该公司是一家为无创病人监护提供医疗器械的公开上市的制造商。在Digene公司（Digene Corporation）于2007年被收购之前，他还担任其4年的董事，该公司是一家公开上市的生物技术公司。他曾该公司董事会审计委员会主席及薪酬委员会成员。 Weisshaar先生还担任CenterLight卫生系统公司（CenterLight Health System）董事，该公司是纽约州非以营利为目的的长期护理最大供应商之一。
- Kenneth R. Weisshaar, became a director of Orthofix International in 2004. From 2000 to 2002 Mr. Weisshaar served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Prior to that, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a Bachelor of Science degree from Massachusetts Institute of Technology and an MBA from Harvard Business School. He also serves on the board, and as chair of the board's audit committee, of CAS Medical Systems, Inc., a publicly traded manufacturer of medical devices for non-invasive patient monitoring. Prior to its acquisition in 2007 he also served for four years on the board of Digene Corporation, a publicly traded biotechnology company, where he was chair of the audit committee and a member of the compensation committee. Mr. Weisshaar also serves on the board of CenterLight Health System, one of the largest non-for-profit long-term care providers in New York State.
- Thomas M. Patton
-
Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
Thomas M. Patton has served as a member of the Board since April 2020. He is a seasoned healthcare executive and board member with operational, financial, legal, and transactional experience, from start ups to growth companies, both public and private. He currently is an operating partner advisor with the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic spinal fion device corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsce design and development company from Augt 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010 2019. His prior experience includes roles as co founder and chief executive officer of QDx, Inc., a developer of unique micro fluidic diagnostic technology, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics and accounting from the College of the Holy Cross and a J.D. from Georgetown University Law Center. - Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
- Thomas M. Patton has served as a member of the Board since April 2020. He is a seasoned healthcare executive and board member with operational, financial, legal, and transactional experience, from start ups to growth companies, both public and private. He currently is an operating partner advisor with the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic spinal fion device corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsce design and development company from Augt 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010 2019. His prior experience includes roles as co founder and chief executive officer of QDx, Inc., a developer of unique micro fluidic diagnostic technology, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics and accounting from the College of the Holy Cross and a J.D. from Georgetown University Law Center.
- Gregory P. Rainey
-
Gregory P. Rainey目前在CCI Performance Group（为保健公司提供战略和销售管理咨询的公司）担任总裁。1994年到2004年期间，Rainey先生曾受雇于Stryker公司，并在此担任过各种销售管理职位，其中包括销售部副总裁的职位。Rainey先生还一直在Joint Medical 公司和 U.S. Surgical 公司担任各种销售职务。2013年12月以前，他曾在RTI Biologics（一家知名的无菌生物植入物供应商）的董事会任职；2011年10月以前，在 NuOrtho Surgical公司的董事会任职。Rainey先生现在还在The Community Foundation of Middlesex County（一家在康涅狄格州，德尔塞克斯县的非盈利慈善机构）的董事会任职，并且是营销委员会主席。Rainey先生是Loyola University的研究生，并拥有生物学学士学位。
Gregory P. Rainey is currently President of CCI Performance Group, LLC, which provides strategic and sales management consulting services for healthcare companies. From 1994 to 2004 Mr. Rainey was employed by Stryker Corporation where he held various sales management positions including the position of Vice President of Sales. Mr. Rainey has also held various sales positions with Joint Medical Corporation and U.S. Surgical Corporation. He served on the Board of Directors of RTI Biologics, Inc., a leading provider of sterile biological implants, until December 2013 and served on the Board of Directors of NuOrtho Surgical, Inc. until October 2011. Mr. Rainey also serves as a Board member and Chairman of the Marketing Committee of The Community Foundation of Middlesex County, a non-profit entity dedicated to philanthropy in Middlesex County, Connecticut. Mr. Rainey is a graduate of Loyola University with a B.S. in Biology. - Gregory P. Rainey目前在CCI Performance Group（为保健公司提供战略和销售管理咨询的公司）担任总裁。1994年到2004年期间，Rainey先生曾受雇于Stryker公司，并在此担任过各种销售管理职位，其中包括销售部副总裁的职位。Rainey先生还一直在Joint Medical 公司和 U.S. Surgical 公司担任各种销售职务。2013年12月以前，他曾在RTI Biologics（一家知名的无菌生物植入物供应商）的董事会任职；2011年10月以前，在 NuOrtho Surgical公司的董事会任职。Rainey先生现在还在The Community Foundation of Middlesex County（一家在康涅狄格州，德尔塞克斯县的非盈利慈善机构）的董事会任职，并且是营销委员会主席。Rainey先生是Loyola University的研究生，并拥有生物学学士学位。
- Gregory P. Rainey is currently President of CCI Performance Group, LLC, which provides strategic and sales management consulting services for healthcare companies. From 1994 to 2004 Mr. Rainey was employed by Stryker Corporation where he held various sales management positions including the position of Vice President of Sales. Mr. Rainey has also held various sales positions with Joint Medical Corporation and U.S. Surgical Corporation. He served on the Board of Directors of RTI Biologics, Inc., a leading provider of sterile biological implants, until December 2013 and served on the Board of Directors of NuOrtho Surgical, Inc. until October 2011. Mr. Rainey also serves as a Board member and Chairman of the Marketing Committee of The Community Foundation of Middlesex County, a non-profit entity dedicated to philanthropy in Middlesex County, Connecticut. Mr. Rainey is a graduate of Loyola University with a B.S. in Biology.
- James E. Thomas
-
James E. Thomas是Thomas, McNerney & Partners的联合创始人，并在自1992年起，一直从事保健公司的投资。他曾在主管过Warburg Pincus的医疗技术私募业务，并负责生物科技，制药，医疗设备和诊断公司的投资业务。Thomas目前同时是 Clarus Therapeutics, Inc., Galil Medical Ltd., InnoPharma, Inc., Keystone Dental, Inc. 和 PCI, Inc.的董事。在加入Warburg之前，他曾是伦敦Goldman Sachs International公司的副总裁。他以优异的成绩毕业于宾夕法尼亚大学沃顿商学院，并取得经济学学士学位，还曾获得伦敦政治经济学院的经济学硕士学位。
James E. Thomas is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. He previously headed Warburg Pincus LLC’s medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device, and diagnostic companies. Mr. Thomas is currently a board member of Clarus Therapeutics, Inc. and Keystone Dental, Inc. Prior to joining Warburg, he was a Vice President at Goldman Sachs International in London. He graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received a M.Sc. in Economics from the London School of Economics. - James E. Thomas是Thomas, McNerney & Partners的联合创始人，并在自1992年起，一直从事保健公司的投资。他曾在主管过Warburg Pincus的医疗技术私募业务，并负责生物科技，制药，医疗设备和诊断公司的投资业务。Thomas目前同时是 Clarus Therapeutics, Inc., Galil Medical Ltd., InnoPharma, Inc., Keystone Dental, Inc. 和 PCI, Inc.的董事。在加入Warburg之前，他曾是伦敦Goldman Sachs International公司的副总裁。他以优异的成绩毕业于宾夕法尼亚大学沃顿商学院，并取得经济学学士学位，还曾获得伦敦政治经济学院的经济学硕士学位。
- James E. Thomas is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. He previously headed Warburg Pincus LLC’s medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device, and diagnostic companies. Mr. Thomas is currently a board member of Clarus Therapeutics, Inc. and Keystone Dental, Inc. Prior to joining Warburg, he was a Vice President at Goldman Sachs International in London. He graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received a M.Sc. in Economics from the London School of Economics.
- Kathleen A. Tune
-
Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间，Tune女士曾受雇于Piper Jaffray Companies，并在此担任一名保健分析师，与医疗科技公司合作。在Piper的时候，她曾和包括医疗设备，医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.，并在现在属于Pfizer的一个部门工作，负责新产品的开发；还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职，并且还是非盈利性的Mid-America Health Care Investors Network （MHIN）的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。
Kathleen A. Tune,currently serves as Managing Partner with Capita3, an early-stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019.BS, Biochemistry and Microbiology, Minnesota State University;MS, Veterinary Microbiology; University of Minnesota;MBA, Finance, University of Minnesota Carlson School of Management. - Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间，Tune女士曾受雇于Piper Jaffray Companies，并在此担任一名保健分析师，与医疗科技公司合作。在Piper的时候，她曾和包括医疗设备，医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.，并在现在属于Pfizer的一个部门工作，负责新产品的开发；还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职，并且还是非盈利性的Mid-America Health Care Investors Network （MHIN）的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。
- Kathleen A. Tune,currently serves as Managing Partner with Capita3, an early-stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019.BS, Biochemistry and Microbiology, Minnesota State University;MS, Veterinary Microbiology; University of Minnesota;MBA, Finance, University of Minnesota Carlson School of Management.
高管简历
中英对照 | 中文 | 英文- Jeffery A. Baird
Jeffery A. Baird在2004年1月加入了CASMED公司，并担任首席财务官和秘书。2003年4月到2003年12月期间，Baird先生曾是QDx，Inc。（一家刚起步的从事新的医疗诊断产品的开发公司）的首席财务官。Baird先生在1988年到2002年期间受雇于Novametrix Medical Systems，并担任过许多职务，其中包括主管，财务总监和首席财务官。在加入Novametrix之前，Baird先生曾受雇于 Philips Medical Systems, Inc.（一家医疗诊断成像公司）。
Jeffery A. Baird joined CASMED during January 2004 as Chief Financial Officer and Secretary. From April 2003 to December 2003 Mr. Baird was CFO of QDx, Inc., a start-up venture engaged in the development of novel medical diagnostic products. Mr. Baird was employed by Novametrix Medical Systems, Inc. from 1988 to 2002 and held various positions including Controller, Treasurer, and CFO. Prior to joining Novametrix, Mr. Baird was employed by Philips Medical Systems, Inc., a medical diagnostic imaging company.- Jeffery A. Baird在2004年1月加入了CASMED公司，并担任首席财务官和秘书。2003年4月到2003年12月期间，Baird先生曾是QDx，Inc。（一家刚起步的从事新的医疗诊断产品的开发公司）的首席财务官。Baird先生在1988年到2002年期间受雇于Novametrix Medical Systems，并担任过许多职务，其中包括主管，财务总监和首席财务官。在加入Novametrix之前，Baird先生曾受雇于 Philips Medical Systems, Inc.（一家医疗诊断成像公司）。
- Jeffery A. Baird joined CASMED during January 2004 as Chief Financial Officer and Secretary. From April 2003 to December 2003 Mr. Baird was CFO of QDx, Inc., a start-up venture engaged in the development of novel medical diagnostic products. Mr. Baird was employed by Novametrix Medical Systems, Inc. from 1988 to 2002 and held various positions including Controller, Treasurer, and CFO. Prior to joining Novametrix, Mr. Baird was employed by Philips Medical Systems, Inc., a medical diagnostic imaging company.
- Thomas M. Patton
Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
Thomas M. Patton has served as a member of the Board since April 2020. He is a seasoned healthcare executive and board member with operational, financial, legal, and transactional experience, from start ups to growth companies, both public and private. He currently is an operating partner advisor with the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic spinal fion device corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsce design and development company from Augt 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010 2019. His prior experience includes roles as co founder and chief executive officer of QDx, Inc., a developer of unique micro fluidic diagnostic technology, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics and accounting from the College of the Holy Cross and a J.D. from Georgetown University Law Center.- Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
- Thomas M. Patton has served as a member of the Board since April 2020. He is a seasoned healthcare executive and board member with operational, financial, legal, and transactional experience, from start ups to growth companies, both public and private. He currently is an operating partner advisor with the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic spinal fion device corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsce design and development company from Augt 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010 2019. His prior experience includes roles as co founder and chief executive officer of QDx, Inc., a developer of unique micro fluidic diagnostic technology, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics and accounting from the College of the Holy Cross and a J.D. from Georgetown University Law Center.
- Paul B. Benni
Paul B. Benni在1998年加入了CASMED，并在2006年成为首席科技官。Benni博士是FORE-SIGHT Tissue Oximeter的主要发明人员，这是一个基于红外光谱的使用不同波长的光来检测大脑和人体其它器官血氧饱和度的仪器。有了国家卫生组织的资助，Benni博士在2007年为CASMED研发FORE-SIGHT，并使其商业化。Benni博士毕业于罗格斯大学，并在1990年获得电气工程的学士学位，在1999年获得以近红外光谱的研究为重点的生物化学工程博士学位。在加入研究生学院之前，他曾在GE航空公司在微信和火星探测器的工程师。Benni博士拥有近红外光谱技术的几项专利，并曾著作过这方面主题的几篇期刊文章。
Paul B. Benni, Ph.D., joined CASMED in 1998 and in 2006 became Chief Scientific Officer. Dr. Benni is the primary inventor of our FORE-SIGHT® Tissue Oximeter, a near-infrared spectroscopy- NIRS- based device to monitor the oxygen saturation of the brain and other tissues of the human body non-invasively by using various wavelengths of light. With the support of several grants from the National Institutes for Health for his unique approach, Dr. Benni made possible the development and first commercialization of FORE-SIGHT for CASMED in 2007. Dr. Benni graduated from Rutgers, The State University of New Jersey, in 1990 with a B.S. in Electrical Engineering and in 1999 with a Ph.D. in Biomedical Engineering focused on NIRS research. Prior to attending graduate school, he worked as an engineer with GE Astrospace on satellites and the Mars Observer spacecraft. Dr. Benni holds several patents on NIRS technology and authored several peer-reviewed journal articles on the topic.- Paul B. Benni在1998年加入了CASMED，并在2006年成为首席科技官。Benni博士是FORE-SIGHT Tissue Oximeter的主要发明人员，这是一个基于红外光谱的使用不同波长的光来检测大脑和人体其它器官血氧饱和度的仪器。有了国家卫生组织的资助，Benni博士在2007年为CASMED研发FORE-SIGHT，并使其商业化。Benni博士毕业于罗格斯大学，并在1990年获得电气工程的学士学位，在1999年获得以近红外光谱的研究为重点的生物化学工程博士学位。在加入研究生学院之前，他曾在GE航空公司在微信和火星探测器的工程师。Benni博士拥有近红外光谱技术的几项专利，并曾著作过这方面主题的几篇期刊文章。
- Paul B. Benni, Ph.D., joined CASMED in 1998 and in 2006 became Chief Scientific Officer. Dr. Benni is the primary inventor of our FORE-SIGHT® Tissue Oximeter, a near-infrared spectroscopy- NIRS- based device to monitor the oxygen saturation of the brain and other tissues of the human body non-invasively by using various wavelengths of light. With the support of several grants from the National Institutes for Health for his unique approach, Dr. Benni made possible the development and first commercialization of FORE-SIGHT for CASMED in 2007. Dr. Benni graduated from Rutgers, The State University of New Jersey, in 1990 with a B.S. in Electrical Engineering and in 1999 with a Ph.D. in Biomedical Engineering focused on NIRS research. Prior to attending graduate school, he worked as an engineer with GE Astrospace on satellites and the Mars Observer spacecraft. Dr. Benni holds several patents on NIRS technology and authored several peer-reviewed journal articles on the topic.
- John K. Gamelin
John K. Gamelin在2009年加入CASMED，并在2010年开始担任研发部主管，并在2012年被任命为研发部副总裁。他在研究光学，声学和电子仪器，从研究概念到商业生产，有20余年的经历。此前，他曾是Tellium（一家光学开关公司）的联合创始人和工程部副总裁。他曾在Bellcore的研究和工程组织担任高级科技人员，并开始自己的职业生涯。Gamelin博士拥有在光交叉连接和交换技术方面的四项美国专利和在生物医学成像和一个医疗设备方面的专利申请。他是超过50篇的包括生物医学成像，激光发射设备主题的出版刊物的作者和合著者。他曾获得加利福尼亚大学的电气工程博士学位。
John K. Gamelin, Ph.D., joined CASMED in 2009 became the Director of Research and Development in 2010 and was appointed as Vice President of Research and Development in 2012. He has more than 20 years of experience inventing and developing optical, acoustic, and electronic instrumentation, from research concept to commercial production. Previously, he was a co-founder and Vice President of Engineering for Tellium, an optical switching company. He began his career as a Senior Scientist at Bellcore, the research and engineering organization for the Regional Bell Operating Companies. Dr. Gamelin holds four U.S. patents in optical cross-connects and switching technology and several patent applications in biomedical imaging and medical instrumentation. He is the author or co-author of more than 50 publications on topics that include biomedical imaging and laser transmitters. He received his Ph.D. in Electrical Engineering from the University of California.- John K. Gamelin在2009年加入CASMED，并在2010年开始担任研发部主管，并在2012年被任命为研发部副总裁。他在研究光学，声学和电子仪器，从研究概念到商业生产，有20余年的经历。此前，他曾是Tellium（一家光学开关公司）的联合创始人和工程部副总裁。他曾在Bellcore的研究和工程组织担任高级科技人员，并开始自己的职业生涯。Gamelin博士拥有在光交叉连接和交换技术方面的四项美国专利和在生物医学成像和一个医疗设备方面的专利申请。他是超过50篇的包括生物医学成像，激光发射设备主题的出版刊物的作者和合著者。他曾获得加利福尼亚大学的电气工程博士学位。
- John K. Gamelin, Ph.D., joined CASMED in 2009 became the Director of Research and Development in 2010 and was appointed as Vice President of Research and Development in 2012. He has more than 20 years of experience inventing and developing optical, acoustic, and electronic instrumentation, from research concept to commercial production. Previously, he was a co-founder and Vice President of Engineering for Tellium, an optical switching company. He began his career as a Senior Scientist at Bellcore, the research and engineering organization for the Regional Bell Operating Companies. Dr. Gamelin holds four U.S. patents in optical cross-connects and switching technology and several patent applications in biomedical imaging and medical instrumentation. He is the author or co-author of more than 50 publications on topics that include biomedical imaging and laser transmitters. He received his Ph.D. in Electrical Engineering from the University of California.